Wellington's first biotech-focused PE fund raises $393M

Wellington Management has closed its first private equity fund focused on drug discovery and development companies at $393 million.

Bob Deresiewicz will manage Wellington Biomedical Innovation Fund I, which was oversubscribed and will invest in companies working in areas including oncology, inherited diseases, rare diseases, gene therapy, diagnostics and neurobiology...